JP2013508315A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508315A5
JP2013508315A5 JP2012534543A JP2012534543A JP2013508315A5 JP 2013508315 A5 JP2013508315 A5 JP 2013508315A5 JP 2012534543 A JP2012534543 A JP 2012534543A JP 2012534543 A JP2012534543 A JP 2012534543A JP 2013508315 A5 JP2013508315 A5 JP 2013508315A5
Authority
JP
Japan
Prior art keywords
solution
external
pharmaceutical composition
nacl
internal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012534543A
Other languages
English (en)
Japanese (ja)
Other versions
JP5778160B2 (ja
JP2013508315A (ja
Filing date
Publication date
Priority claimed from DKPA200901150A external-priority patent/DK177529B1/en
Application filed filed Critical
Publication of JP2013508315A publication Critical patent/JP2013508315A/ja
Publication of JP2013508315A5 publication Critical patent/JP2013508315A5/ja
Application granted granted Critical
Publication of JP5778160B2 publication Critical patent/JP5778160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012534543A 2009-10-23 2010-10-25 sPLA2加水分解性リポソームを含む医薬組成物 Expired - Fee Related JP5778160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200901150A DK177529B1 (en) 2009-10-23 2009-10-23 Liposomes with improved storage stability
DKPA200901150 2009-10-23
PCT/DK2010/050283 WO2011047689A2 (en) 2009-10-23 2010-10-25 Liposomes with improved storage stability

Publications (3)

Publication Number Publication Date
JP2013508315A JP2013508315A (ja) 2013-03-07
JP2013508315A5 true JP2013508315A5 (show.php) 2013-04-18
JP5778160B2 JP5778160B2 (ja) 2015-09-16

Family

ID=43533079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534543A Expired - Fee Related JP5778160B2 (ja) 2009-10-23 2010-10-25 sPLA2加水分解性リポソームを含む医薬組成物

Country Status (16)

Country Link
US (1) US9820941B2 (show.php)
EP (1) EP2490671B1 (show.php)
JP (1) JP5778160B2 (show.php)
CN (1) CN102639114B (show.php)
AU (1) AU2010310240B2 (show.php)
CA (1) CA2772973C (show.php)
CY (1) CY1115139T1 (show.php)
DK (2) DK177529B1 (show.php)
ES (1) ES2465565T3 (show.php)
HR (1) HRP20140413T1 (show.php)
PL (1) PL2490671T3 (show.php)
PT (1) PT2490671E (show.php)
RS (1) RS53321B (show.php)
SI (1) SI2490671T1 (show.php)
SM (1) SMT201400065B (show.php)
WO (1) WO2011047689A2 (show.php)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
HRP20202030T1 (hr) * 2014-04-30 2021-02-19 Fujifilm Corporation Liposomska kompozicija i postupak za njeno dobivanje
JP6276847B2 (ja) * 2014-04-30 2018-02-07 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3138557B1 (en) * 2014-04-30 2023-06-07 FUJIFILM Corporation Liposome composition and method for producing same
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2019200325A1 (en) * 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
CN112334140A (zh) 2018-06-20 2021-02-05 富士胶片株式会社 包含内含吉西他滨的脂质体组合物及免疫检查点抑制剂的组合医药

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JP2931981B2 (ja) * 1988-03-04 1999-08-09 武田薬品工業株式会社 リポソーム製剤およびその製造法
ATE77051T1 (de) 1988-03-04 1992-06-15 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
FI895340A7 (fi) * 1988-11-14 1990-05-15 Bristol Myers Squibb Co Hypertoninen cisplatin-liuos
JPH05194192A (ja) * 1991-08-21 1993-08-03 Shionogi & Co Ltd 分散性の改善された温度感受性mlv型リポソ−ム
JPH069374A (ja) * 1992-04-07 1994-01-18 Banyu Pharmaceut Co Ltd リポソ−ム製剤およびその製造法
AU3559695A (en) 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
PT929293E (pt) * 1996-08-23 2004-03-31 Sequus Pharm Inc Lipossomas contendo um composto de cisplatina
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
EP1254143B1 (en) 2000-02-10 2004-09-29 Liplasome Pharma A/S Lipid-based drug delivery systems
US7166297B2 (en) 2000-04-12 2007-01-23 Liplasome Pharma A/S Lipid-based drug delivery systems against parasitic infections
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
PT1443900E (pt) 2001-11-13 2012-08-01 Celator Pharmaceuticals Inc Composições de veículo lipídico com estabilidade melhorada no sangue
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
GB0312309D0 (en) * 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US20070286898A1 (en) 2004-08-31 2007-12-13 Astellas Pharma Inc. Intracellular Drug Delivery Improving Liposome
ATE418966T1 (de) 2004-11-03 2009-01-15 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid- derivaten und ihre therapeutische verwendung
TW200726485A (en) * 2005-07-01 2007-07-16 Alza Corp Liposomal delivery vehicle for hydrophobic drugs
CN101040853B (zh) * 2006-03-22 2010-05-12 上海医药工业研究院 一种草乌甲素多泡脂质体及其制备方法
JP2009530318A (ja) 2006-03-23 2009-08-27 リプラサム ファーマ アー/エス 加水分解時に分子内環化反応を行うホスホリパーゼa2分解性脂質を含む脂質ベース薬剤送達系
JP5248492B2 (ja) 2006-07-14 2013-07-31 エフエムシー バイオポリマー エイエス 低分子量アルギネートを含むヒドロゲルおよびそれから製造されたバイオ構造物
CN100563646C (zh) * 2007-07-13 2009-12-02 陈祥峰 一种奥沙利铂脂质体葡萄糖制剂的制备方法
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery

Similar Documents

Publication Publication Date Title
JP2013508315A5 (show.php)
JP2014051497A5 (show.php)
JP2009531457A5 (show.php)
JP2012255026A5 (show.php)
JP2014520852A5 (show.php)
FI3223838T3 (fi) Kultakiivin koostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi
JP2013509429A5 (show.php)
NZ602685A (en) Concentrated protein formulations and uses thereof
JP2013518107A5 (show.php)
JP2014507482A5 (show.php)
JP2010166916A5 (show.php)
PH12013500454A1 (en) Substituted imidazopyridazines
TR200806298A2 (tr) Farmasötik formülasyon
MA35110B1 (fr) Protéines de fusion et polyvaccins comprenant la protéine e et la piline a d'haemophilus influenzae
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
MX340985B (es) Compuestos de n-heteroarilo.
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
CN102036649A8 (zh) 精氨酸盐及其治疗口腔疾病的用途
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2013514797A5 (show.php)
JP2013507408A5 (show.php)
MX2009011218A (es) Microparticulas de acido nucleico para administracion pulmonar.
HRP20140413T1 (hr) Spla2 hidrolizirajuä†i liposomi s poboljšanim svojstvima pohranjivanja
JP2014503593A5 (show.php)
JP2012529293A5 (show.php)